Literature DB >> 33820781

Standardized Uptake Value for 18F-Fluorodeoxyglucose Is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer.

John M Floberg1,2, Jin Zhang1, Naoshad Muhammad1, Todd A DeWees3, Matthew Inkman1, Kevin Chen4, Alexander J Lin1, Ramachandran Rashmi1, Kay Jayachandran1, Brian T Edelson5, Barry A Siegel6,7, Farrokh Dehdashti6,7, Perry W Grigsby1,6,7, Stephanie Markovina1,7, Julie K Schwarz8,7,9.   

Abstract

PURPOSE: Chemoradiotherapy for locally advanced cervical cancer fails in over a third of patients. Biomarkers with therapeutic implications are therefore needed. We investigated the relationship between an established prognostic marker, maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography, and the inflammatory and immune state of cervical cancers. EXPERIMENTAL
DESIGN: An SUVmax most prognostic for freedom from progression (FFP) was identified and compared with known prognostic clinical variables in a cohort of 318 patients treated with definitive radiation with prospectively collected clinical data. Gene set enrichment analysis (GSEA) and CIBERSORT of whole-transcriptome data from 68 patients were used to identify biological pathways and immune cell subpopulations associated with high SUVmax. IHC using a tissue microarray (TMA, N = 82) was used to validate the CIBERSORT findings. The impact of macrophages on cervical cancer glucose metabolism was investigated in coculture experiments.
RESULTS: SUVmax <11.4 was most prognostic for FFP (P = 0.001). The GSEA showed that high SUVmax is associated with increased gene expression of inflammatory pathways, including JAK/STAT3 signaling. CIBERSORT and CD68 staining of the TMA showed high SUVmax tumors are characterized by a monocyte-predominant immune infiltrate. Coculture of cervical cancer cells with macrophages or macrophage-conditioned media altered glucose uptake, and IL6 and JAK/STAT3 signaling contribute to this effect.
CONCLUSIONS: SUVmax is a prognostic marker in cervical cancer that is associated with activation of inflammatory pathways and tumor infiltration of myeloid-derived immune cells, particularly macrophages. Macrophages contribute to changes in cervical cancer glucose metabolism.See related commentary by Williamson et al., p. 4136. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33820781      PMCID: PMC8338789          DOI: 10.1158/1078-0432.CCR-20-4450

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Authors:  Herbert I Hurwitz; Nikhil Uppal; Stephanie A Wagner; Johanna C Bendell; J Thaddeus Beck; Seaborn M Wade; John J Nemunaitis; Philip J Stella; J Marc Pipas; Zev A Wainberg; Robert Manges; William M Garrett; Deborah S Hunter; Jason Clark; Lance Leopold; Victor Sandor; Richard S Levy
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

2.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

3.  18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response.

Authors:  Charles Kunos; Tomas Radivoyevitch; Fadi W Abdul-Karim; Peter Faulhaber
Journal:  Int J Gynecol Cancer       Date:  2011-08       Impact factor: 3.437

4.  Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer.

Authors:  Julie K Schwarz; Jacqueline E Payton; Ramachandran Rashmi; Tao Xiang; Yunhe Jia; Phyllis Huettner; Buck E Rogers; Qin Yang; Mark Watson; Janet S Rader; Perry W Grigsby
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

Review 5.  From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Authors:  Richard L Wahl; Heather Jacene; Yvette Kasamon; Martin A Lodge
Journal:  J Nucl Med       Date:  2009-05       Impact factor: 10.057

Review 6.  The NFκB Signaling Pathway in Papillomavirus-induced Lesions: Friend or Foe?

Authors:  Rui M Gil DA Costa; Margarida M S M Bastos; Rui Medeiros; Paula A Oliveira
Journal:  Anticancer Res       Date:  2016-05       Impact factor: 2.480

7.  Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging-guided high-dose-rate and positron emission tomography/computed tomography-guided intensity modulated radiation therapy.

Authors:  Pawel Dyk; Naomi Jiang; Baozhou Sun; Todd A DeWees; Kathryn J Fowler; Vamsi Narra; Jose L Garcia-Ramirez; Julie K Schwarz; Perry W Grigsby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-20       Impact factor: 7.038

8.  Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

Review 9.  STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance.

Authors:  Valeria Poli; Annalisa Camporeale
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

10.  Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.

Authors:  Stephanie Markovina; Songyan Wang; Lauren E Henke; Cliff J Luke; Stephen C Pak; Todd DeWees; John D Pfeifer; Julie K Schwarz; Weijun Liu; Shuai Chen; David Mutch; Xiaowei Wang; Matthew A Powell; Barry A Siegel; Farrokh Dehdashti; Gary A Silverman; Perry W Grigsby
Journal:  Br J Cancer       Date:  2017-11-07       Impact factor: 7.640

View more
  4 in total

1.  Development and Validation of a Novel Hypoxia-Related Long Noncoding RNA Model With Regard to Prognosis and Immune Features in Breast Cancer.

Authors:  Peng Gu; Lei Zhang; Ruitao Wang; Wentao Ding; Wei Wang; Yuan Liu; Wenhao Wang; Zuyin Li; Bin Yan; Xing Sun
Journal:  Front Cell Dev Biol       Date:  2021-12-16

2.  SERPINB3 (SCCA1) inhibits cathepsin L and lysoptosis, protecting cervical cancer cells from chemoradiation.

Authors:  Songyan Wang; Cliff J Luke; Stephen C Pak; Victoria Shi; Liyun Chen; Jonathan Moore; Arlise P Andress; Kay Jayachandran; Jin Zhang; Yi Huang; Marina Platik; Anthony A Apicelli; Julie K Schwarz; Perry W Grigsby; Gary A Silverman; Stephanie Markovina
Journal:  Commun Biol       Date:  2022-01-12

3.  Circular RNA coiled-coil domain containing 66 regulates malignant development of papillary thyroid carcinoma by upregulating La ribonucleoprotein 1 via the sponge effect on miR-129-5p.

Authors:  Peipei Li; Junhui Chen; Jun Zou; Wei Zhu; Yan Zang; Hongwu Li
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1 upregulation facilitates esophageal carcinoma progression via the microRNA-5590-3p/programmed cell death-ligand 1 pathway.

Authors:  Jingge Cheng; Qian Yang; Xia Han; Haotian Wang; Kun Wu; Hongye Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.